logo-loader
viewMotif Bio PLC

Motif Bio Plc keen to make its 'best shot at goal' with iclaprim NDA

Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB, NASDAQ:MTFB), tells Proactive Investors they're taking some additional time over the new drug application (NDA) for iclaprim as they're keen to make the strongest possible submission to the US regulator.

The next-generation antibiotic has been developed initially to treat acute bacterial skin and skin structure infections and has successfully negotiated two phase III clinical trials.

Quick facts: Motif Bio PLC

Price: 0.06 GBX

AIM:MTFB
Market: AIM
Market Cap: £291.21 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn Get US FDA approval to move to FastTrack to Phase 2...

CytoDyn (OTCQB: CYDY) CEO Nader Pourhassan joined Steve Darling from Proactive to discuss the company getting U.S. FDA  clearance to start a Phase 2 trial with leronlimab to treat COVID-19 patients with mild to moderate indications.  Pourhassan telling Proactive why they have been...

14 hours, 55 minutes ago

2 min read